Provided by Tiger Trade Technology Pte. Ltd.

SINOMAB BIO-B

1.100
+0.0201.85%
Volume:402.90K
Turnover:439.14K
Market Cap:1.53B
PE:-11.00
High:1.135
Open:1.085
Low:1.075
Close:1.080
52wk High:2.190
52wk Low:0.990
Shares:1.39B
HK Float Shares:1.39B
Volume Ratio:1.03
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.100
ROE:-60.37%
ROA:-14.30%
PB:3.61
PE(LYR):-11.00
PS:227.88

Loading ...

SinoMab BioScience publishes 2025 annual report

Reuters
·
Apr 27

君实生物(SINOMAB BIO-B)2025年显著减亏,股本增长强化资金实力

Bulletin Express
·
Apr 27

Sinomab Bioscience Maintains 1.39 Billion Outstanding Shares in March 2026, Grants 11.57 Million New Options

Bulletin Express
·
Apr 08

BRIEF-Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience

Reuters
·
Apr 03

Hainan Haiyao Says Co Plans to Unload up to 5% Stake in SinoMab BioScience Ltd

THOMSON REUTERS
·
Apr 03

SM17 Phase 2 Trial for Atopic Dermatitis Administers First Dose in China

Stock News
·
Apr 01

SinoMab doses first patient in China Phase 2 trial of SM17 for atopic dermatitis

Reuters
·
Apr 01

SinoMab BioScience says non-executive directors Chen, Dong resign

Reuters
·
Apr 01

SinoMab BioScience files list of directors with Hong Kong Stock Exchange

Reuters
·
Apr 01

SinoMab Announces Resignation of Two Non-Executive Directors Effective March–April 2026

Bulletin Express
·
Mar 31

SinoMab Announces Updated Board Composition and Committee Assignments

Bulletin Express
·
Mar 31

SINOMAB BIO-B Announces Resignation of Non-Executive Director

Stock News
·
Mar 31

SinoMab Announces Positive Phase 1 Bridging Data for Subcutaneous SM17, Preparing Phase 2 Atopic Dermatitis Trial

Bulletin Express
·
Mar 25

Positive Topline Results from SM17 Route Conversion Phase 1 Bridging Study in China

Stock News
·
Mar 25

SinoMab BioScience announces positive topline results for SM17 China Phase 1 route-switch bridging study; AD Phase 2 in China expected to start by mid-FY2026

Reuters
·
Mar 25

SINOMAB BIO-B (03681) Grants 11.5748 Million Share Options

Stock News
·
Mar 24

SinoMab Grants 11.57 Million Share Options at HK$1.94 to Two Employees, Including One Senior Manager

Bulletin Express
·
Mar 24

SinoMab grants 11,574,840 share options at HKD 1.94 per share

Reuters
·
Mar 24

SinoMab BioScience's 2025 Loss Narrows

MT Newswires Live
·
Mar 24

BRIEF-Sinomab Bioscience Posts Loss For Year Rmb105.0 Million

Reuters
·
Mar 23